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As many members of the tumor necrosis factor receptor superfamily, glucocorticoid-induced TNFR-related gene (GITR) plays
multiple roles mostly in the cells of immune system. CD8+ T cells are key players in the immunity against viruses and tumors, and
GITR has been demonstrated to be an essential molecule for these cells to mount an immune response. The aim of this paper is to
focus on GITR function in CD8+ cells, paying particular attention to numerous and recent studies that suggest its crucial role in
mouse disease models.
1.Introduction
Known as an important costimulatory molecule in all
T-cell subsets, glucocorticoid-induced TNFR-related gene
(GITR), a member of the TNFR superfamily, is considered
a key regulator in a multitude of immune functions and
in some tissues [1, 2]. GITR is expressed and further
upregulated on most immune cell types like T regulatory
cells (Tregs), na¨ ıve T cells, natural killer cells (NKs), and
at low levels in B cells, macrophages, and dendritic cells
[3, 4]. Diﬀerent splicings of GITR gene have been identiﬁed,
including a soluble form [5]. GITR’s role has been studied
in a number of physiological conditions and cells like ker-
atinocytes [6], bone [7], sympathetic neuron development
[8], bone marrow stromal cells [9], microglia [10], and in a
variety of autoimmune/inﬂammatory pathologies in murine
models. Such studies reveal GITR as a pivotal mediator
in inﬂammation processes and autoimmune diseases as
described in murine experimental colitis [11, 12], acute
and chronic inﬂammation of the lung [13, 14], collagen-
induced arthritis [15], splanchnic artery occlusion (SAO)
shock [16], thyroiditis [17], experimental autoimmune
encephalomyelitis [18], acute pancreatitis [19], and multiple
organ dysfunction syndrome (MODS) [20]. Despite their
name, glucocorticoids are unnecessary for GITR upregula-
tion [21], unlike demonstrated for another glucocorticoid-
induced gene [22, 23]. GITR-derived signals promote an
inﬂammatory environment as indicated by the attenuated
course taken by GITR−/− mice during the aforementioned
autoimmune/inﬂammatory experimental diseases.
GITR is triggered by its ligand (GITRL), mainly
expressed in antigen-presenting cells and endothelial cells
[24, 25]. The costimulatory eﬀect of GITR triggering in
T cells, both conventional CD4+ and CD8+ cells, causes
enhanced T-cell expansion and cytokine production [26–
30]. Conversely, GITR engagement in NK cells induces an
inhibitory eﬀect [31–33], even though a separate study
provides opposite results [34]. Costimulation by GITR is
also found either to activate [35] or to inhibit NKT cells
[36] .T h er o l ep l a y e db yG I T Ri nT r e g sa p p e a r st ob e
more complex. When it was found highly expressed in Treg
cells,GITRappearedtoabrogateTreg-mediatedsuppression,
when triggered by an anti-GITR mAb [37, 38]. However,
one later study suggested that strong co-activation of eﬀector
T cells was responsible for this eﬀect, since GITR-triggered
eﬀectors were found to be resistant to Treg-mediated sup-
pression [39]. Although GITR inﬂuences Treg function, it
does not take part to the mechanism of suppression, since
we found that GITR-KO Treg cells are able to suppress as
well [26]. Furthermore, an anti-GITR treatment in mouse
tumor models alters the number of tumor inﬁltrating Treg
cells [40], and GITRL transgenic mice show an increased
absolute number of T regulatory cells [41]. So there has2 The Scientiﬁc World Journal
been confusion about the actual function of GITR on Treg
cells. Currently, the most accepted explanation about GITR
functioninTregandTeﬀectorcellsisthatGITRengagement
activates both cells thereby causing resistance of eﬀector cells
to Treg suppression, inhibition of Treg cell activity and Treg
expansion [4, 26, 42–44]. Another piece of the puzzling
function of GITR in Treg cells has been recently added by the
discovery of a human CD4+ subpopulation with regulatory
activity that expresses GITR and CD127 but only low levels
of CD25, so that GITR can now be considered as a marker of
these cells [45, 46].
Recent works have found a correlation between GITR
and some human pathologies: in the pathogenesis of
rheumatoid arthritis (RA), the expression of GITR on
macrophages in human RA synovium may enhance inﬂam-
matory activation of these cells [47]; in atopic dermatitis,
the interaction of GITR with its cognate ligand, GITRL, may
perpetuate local inﬂammation [48]; ﬁnally, one polymor-
phismofGITRgeneseemstobeassociatedwithHashimoto’s
disease prognosis [49]. A separate issue deals with the
relationship of GITR and tumors, well reviewed by Placke
et al. [50]a n dS c h a e re ta l .[ 44], who describe how GITR
importancehasgrownupsinceitwasfoundtobeinvolvedin
tumorrejection,instudiesthatusedanti-GITRantibodiesor
GITR recombinant proteins, as also described below in this
paper. Accordingly, GITR expression in tumor inﬁltrating
lymphocytes (TILs) has been found to be associated with
cancer progression in patients suﬀering from esophageal
adenocarcinomas. Although studies in mice and men could
lead to contrasting conclusions about the exact role of GITR
in the same cell type, many eﬀorts are being made to transfer
the knowledge of GITR function to the clinics. The aim is
the application of tools like anti-GITR mAbs or recombinant
proteins like GITR-Fc to therapy of cancer and infectious or
inﬂammatory diseases.
This paper focuses on the role of GITR in the powerful
modulation of CD8+ T-cell function, a ﬁeld that still needs
more investigation owing to the pivotal role played by CD8+
cells in cancer rejection and infectious diseases.
2. Expressionof GITR in CD8+ TC ell s
Despite the role of GITR has been poorly investigated in
CD8+ cells as compared to the wide range of studies in CD4+
cells,apictureofGITRexpressionandfunctioninCD8+ cells
begins to be elucidated. Mouse CD8+ T cells express GITR at
basal level and upregulate GITR after activation [26, 27, 51–
53], while human CD8+ cells show GITR expression only
after activation [54, 55]. In a study aimed at identifying
molecular markers of human CD8+CD28− cells, GITR is
found to be one of the expressed genes in primed cells
[55], conﬁrming that no GITR can be detected at the
steady state in human CD8+ cells, either in CTLs or in
peripheral regulatory T cells. Only a regulatory population
of human thymic CD8+CD25+ cells spontaneously expresses
GITR. In a pathologic condition such as viral infection,
in vivo kinetics of GITR expression shows its increase on
antigen-speciﬁc CD8+ T cells after ocular HSV infection
in the draining lymph nodes, suggesting an involvement
of GITR/GITRL system in the regulation of virus-induced
immuno-inﬂammatory lesions [56]. Interestingly, GITR
expression is found to be enhanced in CD8+ tumor-speciﬁc
cells thus suggesting an involvement of GITR in CTL-
mediated tumor rejection (see below).
3. The Major Role of GITR in CD8+ Cells
The unquestioned role of GITR as a costimulatory molecule
in T cells has been deeply investigated over the last years and
has yielded a ﬂourishing literature predominantly dealing
with either conventional or Treg CD4+ cells [2, 4, 50].
However, the importance of GITR in CD8+ cells has been
established as well by ex vivo and in vivo studies as described
below. We have demonstrated that the costimulatory role
of GITR is indispensable to fully activate CD8+ cells since
its absence impairs the proliferation response of these
cells to CD28 costimulation [51]. Conversely, CD28−/−
CD8+ cells can be fully activated by GITR costimulation.
Interestingly, no diﬀerences are observed in CD4+ cells
between GITR−/− a n dc o n t r o lm i c e ,s u g g e s t i n gas p e c i ﬁ c
role for GITR-mediated costimulatory signals in CD8+ cells.
As a consequence, NF-κB, one of the best characterized
mediator of GITR signalling pathway, is impaired in CD28-
costimulated GITR−/− CD8+ cells, indicating GITR as a
unique costimulatory molecule independent of CD28 [51].
To support the peculiar role of GITR in CD8+ cells, two
brilliant works have previously demonstrated a separate
function of GITR in CD4+ and CD8+ cells. Muriglan et al.
show that GITR stimulation by an anti-GITR mAb (DTA-
1) enhances alloreactive CD8+CD25− T-cell proliferation
increasing GVHD and exerting opposite eﬀects in allore-
active CD4+CD25− cells [52]. Moreover, Kim et al. show
that the engagement of GITR by the same antibody DTA-1
regulates the ability of donor CD8+ cells to respond while
they are in the process to become tolerant, pushing the
shift from chronic GVHD to acute GVHD [53]. Therefore,
dissecting the immunological mechanisms that determine
the development of GVHD holds therapeutic promise for
manipulation of the GITR/GITRL system in the prevention
of GVHD and other related pathologies.
4. GITR Function in ViralInfections
A few in vivo studies evidence how GITR signals may be
important for antiviral activity of CD8+ cells. In a mouse
model of HSV-1 infection, La and coworkers found that
treatmentwithanti-GITRagonisticantibody(DTA-1)causes
an expansion of both CD4+ and CD8+ cells in the draining
lymph nodes, with a higher increased number of CD8+
cells. Notably, antigen-speciﬁc IFN-γ-secreting CD8+ cells
are increased, suggesting GITR stimulation as an important
mediator of virus clearance by the immune response [57].
The increase in T-cell responses and the reduction in viral
load are also observed when persistently infected mice with
Friend virus are treated with anti-GITR therapy combined
with adoptive transfer of CD8+ cells [58]. In another studyThe Scientiﬁc World Journal 3
bySuvasetal.,thesameanti-GITRantibodyDTA-1enhances
virus-speciﬁc T-cell responses mediated by CD4+ and CD8+.
In particular there is an increase of in vivo CD8+ T-cell
cytotoxicity, as demonstrated [56] by rise in Granzyme B
levels in a mouse model of ocular HSV infection, while a
decrease of proinﬂammatory responses of CD11b+ cells. The
role of GITR stimulation for the expansion of CD8+ cells
is further and deﬁnitely demonstrated by Snell et al. who
use GITR−/− OT-I transgenic mice in an in vivo model of
severe inﬂuenza infection in which puriﬁed CD8+ GITR−/−
OT-I cells are transferred into recipient mice successively
infected with inﬂuenza A/HK-X31-OVA [59]. They ﬁnd that
GITR is critical for CD8+ expansion in both the primary
and secondary response to severe inﬂuenza virus infection
a n di sr e q u i r e df o rC D 8 + survival. Of note anti-GITR
DTA-1 antibody induces an enhanced expression of BcL-
xL, a prosurvival molecule downstream of NF-κB, previously
showntobeimportantinCD8+ cells in GITR-suﬃcientmice
[51].
Overall, all studies frame GITR as a pivotal molecule
in CD8+ cells, which seems to contribute to viral clearance
and mouse survival in infections in which CD8+ cells play
ac r i t i c a lr o l e( Figure 1). The only data in contrast with
the aforementioned studies are obtained analyzing GITRL
transgenic mice, which overexpress GITRL transgene in B
cells, where CD8+ cells are not expanded while both eﬀector
and regulatory CD4+ cell numbers are increased [41]. This
discrepancy can be explained either with a lack of interaction
betweenCD8+ TcellsandBlymphocytesorwiththefactthat
GITRisalreadystimulatedatmaximumlevelsinWTmiceso
that a GITRL increase does not inﬂuence the CD8+ response.
5.GITR,CD8+ Cells, andAntitumorImmunity
Several studies have recently revealed a strong tumor rejec-
tion potential for both the anti-GITR antibody DTA-1 and
the recombinant protein Fc-GITRL [1, 44]. In the attempt
to ﬁnd which cells are involved in such a mechanism, some
studies focused their attention on CD8+ cells. Although
CD4+ cells play a role in mediating anti-GITR-induced
immune activation against tumors [60, 61], CD8+ cells are
indispensable for tumor rejection [60–64]. Studies of T-
cell depletion eﬀectively demonstrate the major role for
CD8+ cells. CD8+ depletion, in combination with Fc-
mGITRL treatment, signiﬁcantly lowers tumor regression as
compared to Fc-mGITRL alone in tumor-bearing BALB/c
mice [63]. In contrast, CD4+ depletion in combination with
Fc-mGITRL treatment results in the same percent tumor
regression as CD4+ depletion alone. Thus, in Fc-mGITRL
immunotherapy, CD8+ cells play a critical role [63]. In
another study, depletion of CD8+ cells in mice injected
with GITRL-expressing tumor cells promotes tumor growth
[65]. Furthermore, Nishikawa et al. demonstrate that GITRL
inhibits CMS5a tumor growth in mice immunized with a
CTL epitope and that depletion of CD8+ cells blocks the
eﬀectofcoadministeredGITRL[66].Finally,Cˆ oteetal.show
that depleting CD8+ cells together with the administration
of anti-GITR Ab, at the time of inducing the primary
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Figure 1: GITR function in antiviral immunity. Treatment with
anti-GITR antibody induces activation of CD8+ cells through
upregulation of GITR, release of IFN-γ,G r a n z y m eB ,a n dn u c l e a r
translocation of NF-κB with subsequent transcription of target
genes. GITRL is expressed in dendritic cells.
tumor, signiﬁcantly reduces the number of mice rejecting
secondary tumors [67]. Therefore, T-cell-speciﬁc depletion
studiesinvariablyshowthatGITRstimulation,eitherbyanti-
GITR antibodies or recombinant GITRL proteins, activates
CD8+ response against tumor, which appears to be crucial
for tumor rejection.
Also studies of T-cell transfer further support CD8+
involvement in tumor rejection that seems to be somehow
GITR-dependent. The study by Imai et al. shows that
adoptively transferred CD8+ cells speciﬁc for the CMS5
tumor antigen mERK2 in tumor-challenged BALB/c mice
induce tumor regression. Such eﬀect is enhanced by the
coadministration of anti-GITR DTA-1 mAb [62]. Another
study demonstrates that anti-GITR treatment together with
CD8+ cells in SCID recipient mice is suﬃcient to reject the
tumor, while CD4+ transferred cells are not, although CD4+
cells play a central role in helping the functions of CD8+,
NK and B cells [60]. Therefore, the cytolytic activity of CD8+
cells induced by GITR engagement is essential for successful
tumor eradication.
But how do CD8+ cells exert their action? Do they
expand? Experiments performed in vivo with various GITRL
recombinant proteins and anti-GITR antibodies prove that
the presence of the ligand, either inside the tumor or
as a soluble molecule, or treatment with anti-GITR anti-
body augments CD8+ expansion and activity. These results
conﬁrm that GITR acts as a costimulatory molecule in
CD8+ cells. Piao et al. use i.p. inoculated GITRL+ tumors to
study CD8+ cell response and ﬁnd an enhanced cytotoxicity4 The Scientiﬁc World Journal
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Figure 2: GITR function in antitumoral immunity. Treatment
with anti-GITR antibody and GITRL recombinant protein induces
activation of CD8+ cells through upregulation of GITR, release of
IFN-γ andGranzymeB.Thereisevidencethatsometumorsexpress
GITRL.
and number of these cells [65]. Hu et al. use a soluble Fc-
mGITRL in two BALB/c tumor models and demonstrate
an increased CD8+ activity and Granzyme B production
between controls and treated mice [63]. Another interesting
study by Cho et al. induces ectopic expression of GITRL
in tumor that causes accumulation and increase of activity
of CD8+ cells [68]. Calmels et al. demonstrate that GITRL
recombinant protein causes enhanced cell inﬁltration of
both CD4+ and CD8+ cells once injected into the tumor
[61]. GITRL, therefore, seems to be the key molecule to
induce activation in CD8+ cells, which expand when GITR
is triggered by its cognate ligand.
A contribute to antitumor immunity comes from GITRL
transfection in dendritic cells, either murine or human,
which have been demonstrated to cause expansion and
intratumor accumulation of CD8+ antigen-speciﬁc IFN-γ-
secreting cells. Once more the forced expression of GITRL
enhances the cytolytic and antitumor activity of CD8+
cells, which are able to delay tumor growth through the
productionofIFN-γ [69,70].WhetherGITRLisupregulated
in solid tumors is still an open ﬁeld, since its expression
has been found in AML [31] and in some cell lines such as
HUVEC EA.Hy926 or EBV-transformed B cell [70], but no
study is so far available about GITRL expression in murine
or human solid tumors (Figure 2).
When the anti-GITR mAb DTA-1 is used in tumor
models, it can activate CD8+ and induce tumor rejection as
GITRL recombinant proteins do. Mitsui et al. demonstrate
that, while CD4+ cells provide essential “help” to activate
CD8+ cells, CD8+ are eﬀectively able to kill tumor cells in
mice that received injection of a murine colon carcinoma
cell line after anti-GITR/anti-CTLA-4 combined treatment.
Moreover the number of tumor-inﬁltrating CD8+ cells is
augmented, reﬂecting an enhanced CD8+ proliferation [40].
Another work by Cohen et al. studies tumor-speciﬁc CD8+
cellsafteradoptive transferand demonstratesthatanti-GITR
treatment augments [21] their activation, proliferation, and
accumulation in the tumor site leading to a long-term
survival [71]. Finally, the work by Cˆ ote et al. demonstrates
that GITR stimulation with the anti-GITR antibody skews
the avidity of polyclonal CD8+ cells to tumor-speciﬁc Ags.
They use a mouse model of melanoma, in which CD8+
cells are the major targets of anti-GITR therapy [67]. Such
studies demonstrate that an anti-GITR antibody may help
ﬁght against tumor cells by stimulating CD8+ cells, opening
the possibility about the use of these molecules in treatment
ofcanceralsoinhumans.Tothisaim,anewclinicaltrialwith
an anti-GITR antibody in the therapy of human melanoma
gainedapprovalinDecember2010(trialno.NCT01239134).
Overall, these studies demonstrate that the use of anti-GITR
mAbs and the treatment, or vaccination, with GITRL fusion
proteinsinduceCD8+ activationleadingeithertoeradication
or reduction of the tumor.
One concern about the use of anti-GITR antibodies is
the possibility of development of autoimmunity. Treatments
with agonistic anti-GITR Ab may induce or exacerbate
autoimmunity through the eﬀect on Treg cells. However,
recent works support the demonstration of no overt autoim-
munity [40, 72], or to a small extent [64], depending
on the route of administration, the anti-GITR dose, the
duration of treatment, and the genetic susceptibility of
the mouse strain used. However, evidence is accumulating
that systemic administration of agonist anti-GITR Ab has
a higher probability to induce autoimmunity than local
administration.Therefore,inouropinion,studiesevaluating
strategies to stimulate GITR preferentially in tumors are
welcome to facilitate the application to human treatment.
Once CD8+ cells are activated by an anti-GITR Ab
or its natural ligand, they expand and become activated
by increasing IFN-γ production [40, 62, 64, 66, 71–73].
So GITR-derived signals make CD8+ lymphocytes able to
proliferate, activate, accumulate into the tumor site, and kill
tumor cells either alone or with the help of other cytolytic
c e l l ss u c ha sN K[ 60]. But how do CD8+ cells manage
their relationship with Treg tumor inﬁltrating cells? Are
they sensitive or resistant to tumor suppression by Tregs?
Tumors contain a large number of inﬁltrating Treg cells,
helping cancer cells to escape immunity. Except one study
[71], some others refer about a proven resistance of in
vivo GITR-stimulated CD8+ cells to tumor Treg suppression
[40, 65, 66, 73]. Therefore, it is possible that CD8+ cells
become locally activated by GITRL+ tumors and escape the
regulatory function of Treg cells.
6. Concluding Remarks
CD8+ cells remain the key players in the ﬁght against
infections and tumors thanks to their cytotoxic activity [74].
GITR has recently come out as an important molecule for
CD8+ activity, and targeting GITR in these cells might be a
potential instrument for treatment of infections and tumorsThe Scientiﬁc World Journal 5
(Figure 1). Vaccination strategies aimed at stimulating GITR
on CD8+ cells will represent one of the future possibilities
for tumor immunotherapy. The transfer of the knowledge
deriving from mouse models to the clinical setting is
hampered by the structural diﬀerences between murine and
human GITR and by the diﬀerences in the tools able to
activate GITR, as recently summarized [1]. Nonetheless,
we believe that the use of biological tools such as GITRL
recombinant proteins might be of beneﬁt to clear viruses and
in local anticancer therapies.
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